Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.
van Kempen ZLE, Hogenboom L, Toorop AA, Steenhuis M, Stalman EW, Kummer LYL, van Dam KPJ, Bloem K, Ten Brinke A, van Ham SM, Kuijpers TW, Wolbink GJ, Loeff FC, Wieske L, Eftimov F, Rispens T, Strijbis EMM, Killestein J; T2B! immunity against SARS-CoV-2 study group.
van Kempen ZLE, et al. Among authors: rispens t.
Ann Neurol. 2023 Jan;93(1):103-108. doi: 10.1002/ana.26534. Epub 2022 Nov 2.
Ann Neurol. 2023.
PMID: 36250739
Free PMC article.